Valerio Therapeutics SA
PAR:ALVIO

Watchlist Manager
Valerio Therapeutics SA Logo
Valerio Therapeutics SA
PAR:ALVIO
Watchlist
Price: 0.1075 EUR -9.66% Market Closed
Market Cap: 52.6m EUR

Operating Margin
Valerio Therapeutics SA

-706.1%
Current
-924%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-706.1%
=
Operating Profit
-12.9m
/
Revenue
1.8m

Operating Margin Across Competitors

No Stocks Found

Valerio Therapeutics SA
Glance View

Market Cap
52.6m EUR
Industry
Biotechnology

Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

ALVIO Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-706.1%
=
Operating Profit
-12.9m
/
Revenue
1.8m
What is the Operating Margin of Valerio Therapeutics SA?

Based on Valerio Therapeutics SA's most recent financial statements, the company has Operating Margin of -706.1%.

Back to Top